Article| Volume 40, ISSUE 4, P525-529, April 2020

Download started.


Real-world effectiveness of Fertistartkit® treatment in women undergoing ART in French clinical practice: a retrospective multicentre study

Published:January 09, 2020DOI:


      Research question

      What is the real-world effectiveness of Fertistartkit® in women undergoing assisted reproductive technology (ART)?


      Retrospective cohort study including anonymized data of women undergoing ovarian stimulation for ART with Fertistartkit between April 2016 and November 2017 and follow-up of clinical outcomes up to February 2018. Data were collected from the electronic patient databases of 12 French ART centres. The main outcome was number of oocytes retrieved. All data were categorized according to female age (<25, 25–29, 30–34, 35–37, 38–39 and >39 years).


      A total of 1006 cycles from 914 women treated with Fertistartkit were included. At the time of first ovarian stimulation in the study, women were 34.9 ± 5.0 years old, with a median body mass index of 22.7 kg/m². Couples had been infertile for more than 4 years, with all patterns of causes of infertility. Ovarian stimulation was started with a median dose of 300 IU (interquartile range [IQR]: 150–300 IU) of Fertistartkit for 10 days (IQR: 9–11 days), so a median total dose of 2700 IU (IQR: 1800–3300 IU). The mean number of oocytes retrieved per cycle was 9.5 ± 6.8, and the mean number of mature oocytes per cycle was 7.4 ± 5.5. The obtained ongoing pregnancy per started cycle was 26.0% (95% confidence interval [CI]: 24.1–27.9) and the obtained ongoing pregnancy per puncture was 27.0% (95% CI: 25.0–29.0).


      This is the first cohort to describe Fertistartkit treatment management in real-life conditions. The real-world data show that Fertistartkit is an effective option for ovarian stimulation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Reproductive BioMedicine Online
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Alviggi C.
        • Cognigni G.E.
        • Morgante G.
        • Cometti B.
        • Ranieri A.
        • Strina I.
        • Filicori M.
        • De Leo V.
        • De Placido G.
        A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF.
        Gynecol. Endocrinol. 2013; 29: 695-699
        • Broekmans F.J.
        • Kwee J.
        • Hendriks D.J.
        • Mol B.W.
        • Lambalk C.B.
        A systematic review of tests predicting ovarian reserve and IVF outcome.
        Hum. Reprod. Update. 2006; 12: 685-718
        • French Biomedicine Agency
        Le rapport médical et scientifique de l'assistance médicale à la procréation et de la génétique humaines en France.
        Activité d'Assistance Médicale à la Procréation. 2016; (2016)
        • Hershkop E.
        • Segal L.
        • Fainaru O.
        • Kol S.
        ‘Model’ versus ‘everyday’ patients: can randomized controlled trial data really be applied to the clinic?.
        Reprod. Biomed. 2017; 34 (Online): 274-279
        • Leão R.
        • de B.F.
        • Esteves S.C.
        Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.
        Clinics (Sao Paulo). 2014; 69: 279-293
        • Lockwood G.
        • Cometti B.
        • Bogstad J.
        • Erb K.
        • De Geyter C.
        • Urbancsek J.
        • Trevisan S.
        • Pocate-Cheriet K.
        • de Ziegler D.
        A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources.
        Reprod. Biomed. Online. 2017; 35: 17-27
        • Mol B.W.
        • Bossuyt P.M.
        • Sunkara S.K.
        • Garcia Velasco J.A.
        • Venetis C.
        • Sakkas D.
        • Lundin K.
        • Simón C.
        • Taylor H.S.
        • Wan R.
        • Longobardi S.
        • Cottell E.
        • D'Hooghe T.
        Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients.
        Fertil. Steril. 2018; 109: 968-979
        • Munoz E.
        • Bosch E.
        • Fernandez I.
        • Portela S.
        • Ortiz G.
        • Remohi J.
        • Pellicer A.
        The role of LH in ovarian stimulation.
        Curr Pharm Biotechnol. 2012; 13: 409-416
        • Niederberger C.
        • Pellicer A.
        • Cohen J.
        • Gardner D.K.
        • Palermo G.D.
        • O'Neill C.L.
        • Chow S.
        • Rosenwaks Z.
        • Cobo A.
        • Swain J.E.
        • Schoolcraft W.B.
        • Frydman R.
        • Bishop L.A.
        • Aharon D.
        • Gordon C.
        • New E.
        • Decherney A.
        • Tan S.L.
        • Paulson R.J.
        • Goldfarb J.M.
        • Brännström M.
        • Donnez J.
        • Silber S.
        • Dolmans M.-M.
        • Simpson J.L.
        • Handyside A.H.
        • Munné S.
        • Eguizabal C.
        • Montserrat N.
        • Izpisua Belmonte J.C.
        • Trounson A.
        • Simon C.
        • Tulandi T.
        • Giudice L.C.
        • Norman R.J.
        • Hsueh A.J.
        • Sun Y.
        • Laufer N.
        • Kochman R.
        • Eldar-Geva T.
        • Lunenfeld B.
        • Ezcurra D.
        • D'Hooghe T.
        • Fauser B.C.J.M.
        • Tarlatzis B.C.
        • Meldrum D.R.
        • Casper R.F.
        • Fatemi H.M.
        • Devroey P.
        • Galliano D.
        • Wikland M.
        • Sigman M.
        • Schoor R.A.
        • Goldstein M.
        • Lipshultz L.I.
        • Schlegel P.N.
        • Hussein A.
        • Oates R.D.
        • Brannigan R.E.
        • Ross H.E.
        • Pennings G.
        • Klock S.C.
        • Brown S.
        • Van Steirteghem A.
        • Rebar R.W.
        • LaBarbera A.R.
        Forty years of IVF.
        Fertil. Steril. 2018; 110 (.e5): 185-324
        • Polyzos N.P.
        • Drakopoulos P.
        Management Strategies for POSEIDON's Group 1.
        Front Endocrinol (Lausanne). 2019; 10: 679
        • Schneeweiss S.
        Real-World Evidence of Treatment Effects: The Useful and the Misleading.
        Clin. Pharmacol. Ther. 2019; 106: 43-44


      Paul Barrière, MD, PhD, graduated from Nantes University and founded the ART Center in CHU Nantes, one of the largest public centres and one of five PGD programmes in France. He has had a longstanding interest in ovarian stimulation since the late 1980s, since his work on agonist protocols.
      Key Message
      In a real-world setting, Fertistartkit® is an efficient and safe option for controlled ovarian stimulation in assisted reproductive technology. It appreciates and completes the knowledge gained from previous randomised clinical trials, as it concerns larger, non-selected and more inclusive populations of patients and practitioners that better reflect actual practices.